Search
Congratulations to three outstanding The Kids Research Institute Australia researchers who have received second chance WA health funding designed to support researchers who have narrowly missed out on highly competitive national funding.
Almost one in five children across four remote Kimberley communities has some form of chronic lung disease, according to a new study co-designed and conducted in partnership with Aboriginal communities.
Two researchers focused on improving outcomes for children with chronic lung disease and averting suicide contagion and suicide clusters in young people have won prestigious Investigator Grants from the National Health and Medical Research Council.
Charlie, 6, has ended up in hospital twice with invasive Strep A infection over his short lifetime – the first time when just three years old.
The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.
Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
The abstract screening process of systematic reviews can take thousands of hours by two researchers. We aim to determine the reliability and validity of Research Screener, a semi-automated abstract screening tool within a systematic review on non-specific and broader effects of respiratory vaccines on acute lower respiratory infection hospitalisations and antimicrobial prescribing patterns in young children.
The nasal epithelium is the primary point of contact for inhaled respiratory viruses such as rhinovirus, respiratory syncytial virus, influenza, and coronavirus, among others. In order to establish infection, these viruses must engage their respective receptors located on host epithelial cells and begin replication.
To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).